Monoclonal antibodies that conjugate EGFRvIII and their use

Monoclonal antibodies specifically targeting EGFRvIII provide a means to inhibit tumor growth and detect cancer by binding to this variant receptor, addressing the need for targeted cancer treatment.

JP2026086539APending Publication Date: 2026-05-26THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP Β· JP
Patent Type
Applications
Current Assignee / Owner
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Filing Date
2026-02-04
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

There is a need for antibodies that can specifically bind to EGFRvIII, a variant of the epidermal growth factor receptor associated with cancer, without binding to wild-type EGFR, to facilitate targeted cancer treatment.

Method used

Development of monoclonal antibodies and their antigen-binding fragments that specifically recognize EGFRvIII, along with conjugates and chimeric antigen receptors, which can be used to inhibit tumor growth and detect EGFRvIII expression.

Benefits of technology

These antibodies effectively target and inhibit tumors expressing EGFRvIII, reducing tumor growth and metastasis, and can be used in various cancer types including glioma, head and neck cancer, and breast cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026086539000064
    Figure 2026086539000064
  • Figure 2026086539000065
    Figure 2026086539000065
  • Figure 2026086539000066
    Figure 2026086539000066
Patent Text Reader

Abstract

This provides an antibody that can bind to EGFRvIII but not to wild-type EGFR. [Solution] Monoclonal antibodies and antigen-binding fragments that specifically bind to epidermal growth factor receptor (EGFR) variant (v)III, their conjugates, and chimeric antigen receptors are disclosed. Nucleic acid molecules encoding heavy and light chain domains of antibodies and chimeric antigen receptors (CARs) are also disclosed, as are host cells expressing these nucleic acid molecules. Furthermore, the use of these monoclonal antibodies, antigen-binding fragments, conjugates, and T cells expressing CARs is disclosed, for example, for the treatment of tumors expressing EGFRvIII. A method for detecting tumors expressing EGFRvIII is also disclosed.
Need to check novelty before this filing date? Find Prior Art